



Dr.Reddy's 

GASTRONOMY 4.0



14 **OCT**
2022
FRIDAY



5:00 PM
-
9:00 PM



Join virtually



Program Director

Dr. Senthil Rajappa

Sr. Consultant Medical Oncologist,
Basavatarakam Indo American
Cancer Hospital & Research Institute,
Hyderabad



Program Co-ordinator

Dr. Viraj Lavingia

Consultant Medical Oncologist,
HCG Cancer Hospital,
Ahmedabad

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

Click link below for Registration
<https://riverroute.in/gastronomy>

Virtual Meeting Managed by
riverroute
Leaders in Streaming Modules

GASTRONOMY 4.0

Scientific Program

UPPER GI CANCERS | Time 05:00 PM to 6:00 PM

05:00 PM - 05:05 PM

FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO

Speaker: Dr. Bhavesh Poladia

05:05 PM - 05:10 PM

Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen

Speaker: Dr. Palanki Satya Dattatreya

05:10 PM - 05:15 PM

Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK

Speaker: Dr. Arun Chandrasekharan

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

Click link below for Registration

Virtual Meeting Managed by
rivezzroute
Leaders in Streaming Modules

GASTRONOMY 4.0

Scientific Program

UPPER GI CANCERS | Time 5:00 PM to 6:00 PM

05:15 PM - 05:20 PM

Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study)

Speaker: Dr. Rakesh Reddy B

05:20 PM - 06:00 PM

PANEL DISCUSSION

Moderator: Dr. M Vamshi Krishna

Panelists: Dr. Prasad Narayan, Dr. E Prasad, Dr. Harish Peshwe, Dr. Boman Dhabhar, Dr. Rajat Saha, Dr. Shrikant Tiwari

HCC | Time 6:00 PM to 7:00 PM

06:00 PM - 06:05 PM

Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Speaker: Dr. Akash Tiwari

06:05 PM - 06:10 PM

Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Speaker: Dr. Javvid Muzamil

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

Click link below for Registration
<https://riverroute.in/gastronomy>

Virtual Meeting Managed by
riverroute
Leaders in Streaming Modules

GASTRONOMY 4.0

Scientific Program

HCC | Time 6:00 PM to 7:00 PM

06:10 PM - 06:15 PM

Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

Speaker: Dr. Vikas Talreja

06:15 PM - 06:20 PM

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA

Speaker: Dr. Joydeep Ghosh

06:20 PM - 07:00 PM

PANEL DISCUSSION

Moderator: Dr. T. P. Sahoo

Panelists: Dr. Vineet Govind Gupta, Dr. Vignesh Kanda Kumar, Dr. Vipul Doshi, Dr. Amit Dutt Dwary, Dr. Divyesh Goyal, Dr. J Kanan, Dr. Sameer Shrirangwar

PANCREATICOBILIARY CANCERS | Time 7:00 PM to 8:00 PM

07:00 PM - 07:05 PM

Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study

Speaker: Dr. Chitresh Aggarwal

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

Click link below for Registration
<https://riverroute.in/gastronomy>

Virtual Meeting Managed by
riverroute
Leaders in Streaming Modules

GASTRONOMY 4.0

Scientific Program

PANCREATICOBILIARY CANCERS | Time 7:00 PM to 8:00 PM

07:05 PM - 07:10 PM	<p>PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)</p> <p>Speaker: Dr. Akhil Kapoor</p>
07:10 PM - 07:15 PM	<p>Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study</p> <p>Speaker: Dr. Sushant Mittal</p>
07:15 PM - 07:20 PM	<p>Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial</p> <p>Speaker: Dr. Shruti Kate</p>
07:20 PM - 08:00 PM	<p>PANEL DISCUSSION</p> <p>Moderator: Dr. Amish Vora</p> <p>Panelists: Dr. Pritam Kataria, Dr. Lalit Sharma, Dr. Arun Ramanan, Dr. Ghansyam Biswas, Dr. Praveen, Dr. K Sudheer Reddy</p>

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

GASTRONOMY 4.0

Scientific Program

COLORECTAL CANCERS | Time 8:00 PM to 9:00 PM

08:00 PM - 08:05 PM

Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study

Speaker: Dr. Niraj Bhatt

08:05 PM - 08:10 PM

FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group

Speaker: Dr. Priya Tiwari

08:10 PM - 08:15 PM

New "PARADIGM" in RAS WT mCRC

Speaker: Dr. Krishna Prasad

08:15 PM - 08:20 PM

Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

Speaker: Dr. Vaibhav Choudhary

08:20 PM - 09:00 PM

PANEL DISCUSSION

Moderator: Dr. Anant Ramaswamy

Panelists: Dr. Aseem Samar,

Dr. Lalit Mohan Sharma, Dr. S Suresh,

Dr. Naresh Somani, Dr. Randeep Singh,

Dr. Srinivas Kulkarni, Dr. Murtaza Bohra

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

By accepting this invite to the event, you hereby agree to the T&C at <https://www.drreddys.com/privacy-notice.aspx> in respect of the handling of your personal data by Dr. Reddy's. Your participation at the event shall not be construed to: (a) require you to promote, purchase, prescribe, or otherwise recommend any Company products or services; or (b) interfere with your clinical decision-making.

The opinions expressed in the presentation are solely the views of the speaker.

Click link below for Registration
<https://riverroute.in/gastronomy>

Virtual Meeting Managed by
riverroute
Leaders in Streaming Modules